DB:MINA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Synlogic's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MINA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

5.7%

MINA

5.3%

DE Biotechs

0.2%

DE Market


1 Year Return

-17.9%

MINA

5.5%

DE Biotechs

6.6%

DE Market

Return vs Industry: MINA underperformed the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: MINA underperformed the German Market which returned 6.6% over the past year.


Shareholder returns

MINAIndustryMarket
7 Day5.7%5.3%0.2%
30 Day-13.9%2.8%2.1%
90 Day-0.5%7.8%5.6%
1 Year-17.9%-17.9%5.7%5.5%9.1%6.6%
3 Yearn/a20.5%19.3%6.8%-1.8%
5 Yearn/a49.5%47.1%38.9%20.1%

Price Volatility Vs. Market

How volatile is Synlogic's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Synlogic undervalued compared to its fair value and its price relative to the market?

0.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MINA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MINA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MINA is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: MINA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MINA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MINA is good value based on its PB Ratio (0.6x) compared to the DE Biotechs industry average (5.7x).


Next Steps

Future Growth

How is Synlogic forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

0.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MINA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MINA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MINA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MINA's revenue (84.1% per year) is forecast to grow faster than the German market (6% per year).

High Growth Revenue: MINA's revenue (84.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MINA's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Synlogic performed over the past 5 years?

-24.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MINA is currently unprofitable.

Growing Profit Margin: MINA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MINA is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare MINA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MINA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).


Return on Equity

High ROE: MINA has a negative Return on Equity (-43.63%), as it is currently unprofitable.


Next Steps

Financial Health

How is Synlogic's financial position?


Financial Position Analysis

Short Term Liabilities: MINA's short term assets ($122.2M) exceed its short term liabilities ($6.1M).

Long Term Liabilities: MINA's short term assets ($122.2M) exceed its long term liabilities ($21.7M).


Debt to Equity History and Analysis

Debt Level: MINA is debt free.

Reducing Debt: MINA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MINA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MINA has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 33.2% each year.


Next Steps

Dividend

What is Synlogic current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MINA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MINA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MINA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MINA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MINA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Aoife Brennan (44 yo)

2.33yrs

Tenure

US$1,793,870

Compensation

Dr. Aoife M. Brennan, M.D. M.B., B.Ch., BAO, MMSc serves as Director at FibroGen, Inc. since August 5, 2020. She serves as serves as Director at Cerevance LLC. Dr. Brennan served as Director at Ra Pharmace ...


CEO Compensation Analysis

Compensation vs Market: Aoife's total compensation ($USD1.79M) is above average for companies of similar size in the German market ($USD478.34K).

Compensation vs Earnings: Aoife's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Aoife Brennan
President2.33yrsUS$1.79m0.31%
$ 195.2k
Richard Riese
Chief Medical Officer1yrUS$483.42k0.063%
$ 39.6k
Timothy Lu
Co-Founderno datano datano data
James Collins
Co-Founderno datano datano data
Gregg Beloff
Interim CFO0.92yrno data0%
$ 0
Antoine Awad
Chief Operating Officer0.17yrno data0.075%
$ 46.9k
Daniel Rosan
Head of Corporate Finance & Investor Relations0.67yrno datano data
David Hava
Chief Scientific Officerno datano datano data
Elizabeth Wolffe
Head of Investor Relations & Corporate Communicationsno datano datano data
Adam Thomas
Chief People Officer & Secretary2.92yrsno datano data
Caroline Kurtz
Head of Translational Sciences & Product Development4yrsno datano data
Michael Slater
Head of Regulatory Affairs1yrno datano data

1.0yrs

Average Tenure

53yo

Average Age

Experienced Management: MINA's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Aoife Brennan
President2.33yrsUS$1.79m0.31%
$ 195.2k
Richard Shea
Independent Director3.08yrsUS$94.97k0.022%
$ 13.8k
Peter Barrett
Independent Chairman3.5yrsUS$123.53k0%
$ 0
Edward Mathers
Independent Director7.92yrsUS$89.97k0%
$ 0
Chau Khuong
Independent Director3.08yrsUS$84.97k0%
$ 0
Nick Leschly
Independent Director4.5yrsUS$84.97k0.068%
$ 42.6k
Paul Miller
Member Scientific Advisory Boardno dataUS$436.81k0.14%
$ 88.6k
Michael Burgess
Independent Director0.67yrno datano data
Charlotte Hubbert
Observerno datano datano data
Patricia Hurter
Independent Director1.58yrsUS$193.37k0%
$ 0

3.1yrs

Average Tenure

57yo

Average Age

Experienced Board: MINA's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.7%.


Top Shareholders

Company Information

Synlogic, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Synlogic, Inc.
  • Ticker: MINA
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$74.481m
  • Listing Market Cap: US$62.885m
  • Shares outstanding: 34.17m
  • Website: https://www.synlogictx.com

Number of Employees


Location

  • Synlogic, Inc.
  • 301 Binney Street
  • Suite 402
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MINADB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2017
SYBXNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDAug 2017

Biography

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 04:13
End of Day Share Price2020/09/17 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.